GlaxoSmithKline GSK
$50.33 −$0.08 (-0.16%)
Market closed · Nov 7, 9:10 am ET · Last extended-hours $50.33 0.00%
Open$49.07
Prev close$50.41
Day range$48.94 – $50.74
Volume3.19M
Market cap$100.88B
P/E (TTM)17.5
Dividend yield3.56%
Fundamentals
Latest reported quarter: Q3, ended Sep 2026 · reported in GBP
Revenue£8.89B+4.0% YoY
Operating profit£2.13B-18.0% YoY
Net profit£1.70B-20.6% YoY
Diluted EPS£0.76-22.8% YoY
Free cash flow£2.28B+69.5% YoY
Operating cash flow£2.81B
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin72.6%
Operating margin19.1%
Net margin13.0%
Return on equity24.9%
Return on assets6.5%
Return on invested capital13.1%
Current ratio0.86
Liabilities / assets74.4%
Cash & investments£2.96B
Total debt£21.70B
Net cash (debt)-£18.74B
Free cash flow / sales18.7%
This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.
Income statement
| Line item | 2026 Q3 (GBP) |
2026 Q2 (GBP) |
2026 Q1 (GBP) |
2025 ANNUAL (GBP) |
2025 Q4 (GBP) |
|---|---|---|---|---|---|
| Total Revenue as Reported | £8.89B | £8.41B | £7.63B | £32.67B | £8.62B |
| Total Operating Revenue | £8.89B | £8.41B | £7.63B | £32.67B | £8.62B |
| Cost of Revenue | £2.39B | £2.27B | £1.88B | £9.02B | £2.66B |
| Gross Profit | £6.50B | £6.14B | £5.75B | £23.65B | £5.96B |
| Operating Expense | £4.37B | £5.66B | £3.46B | £15.31B | £4.46B |
| Selling and Admin Expenses | £2.38B | £2.20B | £2.12B | £9.09B | £2.64B |
| -General & Admin Expense | £2.38B | £2.20B | £2.12B | £9.09B | £2.64B |
| Research & Development | £1.98B | £3.47B | £1.69B | £7.53B | £2.35B |
| Other Operating Expenses | £262.00M | £198.00M | – | – | – |
| Operating Profit | £2.13B | £481.00M | £2.29B | £8.34B | £1.51B |
| Net Non-Operating Interest Income (Expense) | -£190.00M | -£124.00M | -£145.00M | -£633.00M | -£250.00M |
| Non-Operating Interest Income | £29.00M | £58.00M | £22.00M | £56.00M | -£74.00M |
| Non-Operating Interest Expense | £219.00M | £182.00M | £167.00M | £687.00M | £174.00M |
| Pretax Profit | £1.94B | £354.00M | £2.14B | £7.40B | £950.00M |
| Tax | £232.00M | -£199.00M | £305.00M | £1.11B | £223.00M |
| Net Profit | £1.70B | £553.00M | £1.84B | £6.29B | £727.00M |
| Profit from Continuing Operations | £1.70B | £553.00M | £1.84B | £6.29B | £727.00M |
| Minority Interests | £160.00M | £118.00M | £102.00M | £573.00M | £91.00M |
| Net Income to Parent Company | £1.54B | £435.00M | £1.74B | £5.72B | £636.00M |
| Other Preferred Stock Dividends | £0.00 | £0.00 | £0.00 | £0.00 | £0.00 |
| Net Income to Common Stockholders | £1.54B | £435.00M | £1.74B | £5.72B | £636.00M |
| Basic EPS | £0.77 | £0.22 | £0.86 | £2.82 | £0.32 |
| Diluted EPS | £0.76 | £0.21 | £0.85 | £2.78 | £0.31 |
| Dividend Per Share | £0.33 | £0.34 | £0.35 | £1.29 | £0.33 |
| Total Other Finance Costs | – | – | – | £2.00M | – |
| Special Income (Charges) | – | – | – | -£813.00M | – |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | £581.00M | – |
| -Less:Other Special Charges | – | – | – | £232.00M | – |
Balance sheet
| Line item | 2026 Q3 (GBP) |
2026 Q2 (GBP) |
2026 Q1 (GBP) |
2025 ANNUAL (GBP) |
2025 Q4 (GBP) |
|---|---|---|---|---|---|
| Total Assets | £71.70B | £61.74B | £62.87B | £61.12B | £61.12B |
| Total Current Assets | £17.90B | £17.56B | £17.76B | £17.51B | £17.51B |
| Cash and Cash Equivalents & Short-Term Investments | £2.96B | £3.11B | £3.44B | £3.16B | £3.16B |
| -Cash and Cash Equivalents | £2.93B | £3.11B | £3.44B | £3.15B | £3.15B |
| -Short Term Investments | £28.00M | £1.00M | £1.00M | £9.00M | £9.00M |
| -Accounts Receivable | £8.22B | £7.71B | £7.76B | £5.91B | £5.91B |
| -Taxes Receivable | £302.00M | £368.00M | £181.00M | £799.00M | £799.00M |
| Inventory | £6.30B | £6.28B | £6.16B | £5.92B | £5.92B |
| Total Non-Current Assets | £53.80B | £44.18B | £45.11B | £43.61B | £43.61B |
| Net PPE | £10.12B | £10.03B | £10.04B | £10.05B | £10.05B |
| -Gross PPE | £10.12B | £10.03B | £10.04B | £20.94B | £20.94B |
| -Long Term Equity Investment | £49.00M | £101.00M | £99.00M | £89.00M | £89.00M |
| Financial Assets | £54.00M | £17.00M | £19.00M | £0.00 | £0.00 |
| Goodwill and Other Intangible Assets | £33.39B | £24.18B | £25.43B | £23.77B | £23.77B |
| -Goodwill | £8.22B | £7.38B | £7.29B | £7.02B | £7.02B |
| -Other Intangible Assets | £25.17B | £16.80B | £18.14B | £16.75B | £16.75B |
| Other Non-Current Assets | £2.64B | £2.65B | £2.36B | – | – |
| Total Liabilities | £53.34B | £44.56B | £45.45B | £45.16B | £45.16B |
| Total Current Liabilities | £20.72B | £21.53B | £22.43B | £21.39B | £21.39B |
| Payables | £16.31B | £14.87B | £14.89B | £4.47B | £4.47B |
| -Accounts Payable | £15.63B | £14.34B | £14.34B | £3.54B | £3.54B |
| -Total Tax Payable | £678.00M | £524.00M | £555.00M | £498.00M | £498.00M |
| Short-Term Debt and Capital Lease Obligation | £2.00B | £4.29B | £5.04B | £3.01B | £3.01B |
| Current Provisions | £926.00M | £844.00M | £908.00M | £938.00M | £938.00M |
| Other Current Liabilities | £1.32B | £1.38B | £1.40B | £1.35B | £1.35B |
| Total Non-Current Liabilities | £32.62B | £23.03B | £23.02B | £23.77B | £23.77B |
| Long Term Debt and Capital Lease Obligation | £21.70B | £13.95B | £14.01B | £14.71B | £14.71B |
| Derivative Product Liabilities | £101.00M | £55.00M | £56.00M | £67.00M | £67.00M |
| Non-Current Liabilities | £751.00M | £610.00M | £579.00M | £610.00M | £610.00M |
| Other Non-Current Liabilities | £6.84B | £6.49B | £6.32B | £5.39B | £5.39B |
| Total Equity | £18.36B | £17.18B | £17.42B | £15.96B | £15.96B |
| Stockholders' Equity | £18.75B | £17.65B | £17.85B | £16.38B | £16.38B |
| Capital Stock | £1.35B | £1.35B | £1.35B | £1.35B | £1.35B |
| -Common Stock | £1.35B | £1.35B | £1.35B | £1.35B | £1.35B |
| Additional Paid-In Capital | £3.51B | £3.51B | £3.51B | £3.50B | £3.50B |
| Retained Earnings | £12.46B | £11.46B | £11.59B | £10.21B | £10.21B |
| Minority Interests | -£392.00M | -£468.00M | -£430.00M | -£421.00M | -£421.00M |
| Long Term Accounts Payable and Other Payables | – | – | £66.00M | £896.00M | £896.00M |
| -Other Receivables | – | – | – | £662.00M | £662.00M |
| Prepaid Assets | – | – | – | £385.00M | £385.00M |
| Restricted Cash | – | – | – | £247.00M | £247.00M |
| -Accumulated Depreciation | – | – | – | -£10.89B | -£10.89B |
| -Available for Sale Securities | – | – | – | £790.00M | £790.00M |
| Defined Pension Benefit | – | – | – | £1.12B | £1.12B |
| -Other Payable | – | – | – | £438.00M | £438.00M |
| -Current Debt | – | – | – | £2.88B | £2.88B |
| -Current Capital Lease Obligation | – | – | – | £137.00M | £137.00M |
| Non-Current Accrued Expenses | – | – | – | £6.00M | £6.00M |
| -Long Term Debt | – | – | – | £14.02B | £14.02B |
| -Long Term Capital Lease Obligation | – | – | – | £693.00M | £693.00M |
| Other Equity Interests | – | – | – | -£282.00M | -£282.00M |
Cash flow
| Line item | 2026 Q3 (GBP) |
2026 Q2 (GBP) |
2026 Q1 (GBP) |
2025 ANNUAL (GBP) |
2025 Q4 (GBP) |
|---|---|---|---|---|---|
| Operating Cash Flow | £2.81B | £2.69B | £1.14B | £7.74B | £2.28B |
| Net Income from Continuing Operations | £1.70B | £553.00M | £1.84B | £6.29B | £727.00M |
| Deferred Tax | £232.00M | -£199.00M | £305.00M | £1.11B | £223.00M |
| Other Non-Cash Items | £190.00M | £124.00M | £145.00M | £568.00M | £185.00M |
| Change in Working Capital | £567.00M | £560.00M | -£1.08B | -£1.44B | £872.00M |
| -Change in Other Current Assets | -£423.00M | – | – | -£1.14B | £886.00M |
| -Change in Other Current Liabilities | £990.00M | – | – | £465.00M | £749.00M |
| Net cash flow from investing | -£7.71B | -£789.00M | -£1.47B | -£4.23B | -£933.00M |
| Net PPE Purchase and Sale | -£371.00M | -£325.00M | -£194.00M | -£1.32B | -£560.00M |
| Net Intangibles Purchase and Sale | -£158.00M | -£32.00M | -£160.00M | -£1.52B | -£449.00M |
| Net Business Purchase and Sale | -£7.15B | -£526.00M | -£1.17B | -£1.64B | -£31.00M |
| Net Investment Purchase and Sale | -£29.00M | £0.00 | £9.00M | £11.00M | £0.00 |
| Financing Cash Flow | £4.67B | -£2.15B | £272.00M | -£3.69B | -£856.00M |
| Net Issuance Payments Of Debt | £5.42B | -£632.00M | £1.18B | £1.51B | £548.00M |
| Net Common Stock Issuance | £0.00 | -£307.00M | -£318.00M | -£1.36B | -£251.00M |
| Cash Dividends Paid | -£682.00M | -£727.00M | -£643.00M | -£2.56B | -£646.00M |
| Net Other Financing Charges | £166.00M | -£35.00M | £1.70B | £46.00M | -£25.00M |
| Ending Cash Balance | £2.68B | £2.94B | £3.20B | £3.21B | £3.21B |
| Net Change in Cash | -£229.00M | -£248.00M | -£53.00M | -£177.00M | £489.00M |
| Beginning Cash Balance | £2.94B | £3.20B | £3.25B | £3.40B | £2.76B |
| Effect of Exchange Rate Changes | -£34.00M | -£7.00M | £2.00M | -£19.00M | -£41.00M |
| Free Cash Flow | £2.28B | £2.04B | £698.00M | £4.76B | £1.25B |
| -Change in Receivables | – | – | – | -£1.10B | – |
| -Change in Inventory | – | – | – | -£140.00M | – |
No comments yet — be the first to weigh in on GSK.
Sign in to join the discussion.